2026 Humana Premier Rx Plan (PDP) formulary (drug list)
Contract S5884, plan 156 · Georgia · 3,076 drugs on file · formulary ID 00026402. Each drug links to its cost in every CMS PDP Region 10 plan.
45 drugs starting with X.
| Drug name | Tier | 30-day preferred pharmacy | 90-day mail order | Usage management |
|---|---|---|---|---|
| XALKORI 150 mg Capsule, Coated PelletsCrizotinib | 5Specialty Tier | 33% | N/A |
|
| XALKORI 20 mg Capsule, Coated PelletsCrizotinib | 5Specialty Tier | 33% | N/A |
|
| XALKORI 200 mg CapsuleCrizotinib | 5Specialty Tier | 33% | N/A |
|
| XALKORI 250 mg CapsuleCrizotinib | 5Specialty Tier | 33% | N/A |
|
| XALKORI 50 mg Capsule, Coated PelletsCrizotinib | 5Specialty Tier | 33% | N/A |
|
| XARAH FE KitNorethindrone Acetate And Ethinyl Estradiol And Ferrous Fumarate Tablets | 2Generic | $4.00 | $0.00 | None |
| XARELTO 10 mg Tablet, Film CoatedRivaroxaban | 3Preferred Brand | $45.00 | $125.00 |
|
| XARELTO 15 mg Tablet, Film CoatedRivaroxaban | 3Preferred Brand | $45.00 | $125.00 |
|
| XARELTO 155 mg Granule, For SuspensionRivaroxaban | 3Preferred Brand | $45.00 | $125.00 |
|
| XARELTO 2.5 mg Tablet, Film CoatedRivaroxaban | 3Preferred Brand | $45.00 | $125.00 |
|
| XARELTO 20 mg Tablet, Film CoatedRivaroxaban | 3Preferred Brand | $45.00 | $125.00 |
|
| XARELTO KitRivaroxaban | 3Preferred Brand | $45.00 | $125.00 |
|
| XATMEP 2.5 mg/mL SolutionMethotrexate | 4Non-Preferred Drug | 50% | 50% |
|
| XCOPRI 100 mg Tablet, Film CoatedCenobamate | 4Non-Preferred Drug | 50% | 50% |
|
| XCOPRI 150 mg Tablet, Film CoatedCenobamate | 4Non-Preferred Drug | 50% | 50% |
|
| XCOPRI 200 mg Tablet, Film CoatedCenobamate | 4Non-Preferred Drug | 50% | 50% |
|
| XCOPRI 25 mg Tablet, Film CoatedCenobamate | 4Non-Preferred Drug | 50% | 50% |
|
| XCOPRI 50 mg Tablet, Film CoatedCenobamate | 4Non-Preferred Drug | 50% | 50% |
|
| XCOPRI MAINTENANCE PACK KitCenobamate | 4Non-Preferred Drug | 50% | 50% |
|
| XCOPRI MAINTENANCE PACK KitCenobamate | 4Non-Preferred Drug | 50% | 50% |
|
| XCOPRI TITRATION PACK KitCenobamate | 4Non-Preferred Drug | 50% | 50% |
|
| XCOPRI TITRATION PACK KitCenobamate | 4Non-Preferred Drug | 50% | 50% |
|
| XCOPRI TITRATION PACK KitCenobamate | 4Non-Preferred Drug | 50% | 50% |
|
| XDEMVY 2.5 mg/mL Solution/ DropsLotilaner Ophthalmic Solution | 4Non-Preferred Drug | 50% | 50% |
|
| XERMELO 250 mg TabletTelotristat Ethyl | 5Specialty Tier | 33% | N/A |
|
| XGEVA 120 mg/1.7mL InjectionDenosumab | 5Specialty Tier | 33% | N/A |
|
| XIFAXAN 200 mg TabletRifaximin | 4Non-Preferred Drug | 50% | 50% |
|
| XIFAXAN 550 mg TabletRifaximin | 5Specialty Tier | 33% | N/A |
|
| XOLAIR 300 mg/2mL Injection, SolutionOmalizumab | 5Specialty Tier | 33% | N/A |
|
| XOLAIR 300 mg/2mL Injection, SolutionOmalizumab | 5Specialty Tier | 33% | N/A |
|
| XOLAIR PFS 150 mg/mL Injection, SolutionOmalizumab | 5Specialty Tier | 33% | N/A |
|
| XOLAIR PFS 75 mg/.5mL Injection, SolutionOmalizumab | 5Specialty Tier | 33% | N/A |
|
| XOSPATA 40 mg TabletGilteritinib | 5Specialty Tier | 33% | N/A |
|
| XPOVIO 10 mg Tablet, Film CoatedSelinexor | 5Specialty Tier | 33% | N/A |
|
| XPOVIO 20 mg Tablet, Film CoatedSelinexor | 5Specialty Tier | 33% | N/A |
|
| XPOVIO 20 mg Tablet, Film CoatedSelinexor | 5Specialty Tier | 33% | N/A |
|
| XPOVIO 40 mg Tablet, Film CoatedSelinexor | 5Specialty Tier | 33% | N/A |
|
| XPOVIO 40 mg Tablet, Film CoatedSelinexor | 5Specialty Tier | 33% | N/A |
|
| XPOVIO 50 mg Tablet, Film CoatedSelinexor | 5Specialty Tier | 33% | N/A |
|
| XPOVIO 60 mg Tablet, Film CoatedSelinexor | 5Specialty Tier | 33% | N/A |
|
| XPOVIO 80 mg Tablet, Film CoatedSelinexor | 5Specialty Tier | 33% | N/A |
|
| XTANDI 40 mg CapsuleEnzalutamide | 5Specialty Tier | 33% | N/A |
|
| XTANDI 40 mg TabletEnzalutamide | 5Specialty Tier | 33% | N/A |
|
| XTANDI 80 mg TabletEnzalutamide | 5Specialty Tier | 33% | N/A |
|
| XULANE 150/35 ug/d PatchNorelgestromin And Ethinyl Estradiol | 3Preferred Brand | $45.00 | $125.00 |
|
PA = prior authorization, ST = step therapy, QL = quantity limit. Costs are the plan’s initial-coverage cost-sharing from the CMS 2026 formulary files; a drug not listed here is not on this plan’s formulary, though a formulary exception may still be possible.